Podcasts Health & Fitness Medicine NEJM Interviews NEJM Interview: Dr. James Robinson on the aducanumab experience and the structural factors responsible for high drug prices in the United States.

NEJM Interview: Dr. James Robinson on the aducanumab experience and the structural factors responsible for high drug prices in the United States.

Published: Nov. 24, 2021, 3:01 p.m.

b'Dr. James Robinson is a professor of health economics at the University of California, Berkeley, School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.C. Robinson. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform. N Engl J Med 2021;385:2017-2019.'